At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
patiromer +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients
In Brief
A Phase 2 clinical trial evaluating patiromer and placebo for Hyperkalemia and Heart Failure. Completed, enrolled 120 participants across 33 sites in 7 countries.
Detailed Summary
The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperkalemia, Heart Failure
CountriesCzechia, Georgia, Germany, Poland, Russia, Ukraine, United States
CollaboratorsMedpace, Inc.
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2009
Enrollment StartApr 2009
Primary CompletionNov 2009
Study CompletionDec 2009
TodayJul 2026
First PostedMar 25, 2009
Enrollment StartApr 1, 2009
Primary CompletionNov 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.3 years ago
Interventions
patiromerdrug
Active investigational drug
placebodrug
placebo